A new technique for tracking iron levels in stem cells could help solve one of regenerative medicine’s biggest bottlenecks: inconsistent cell quality. Researchers report that monitoring “iron flux” in mesenchymal stromal cells (MSCs) provides a fast and reliable way to predict their ability to form cartilage – potentially improving treatments for osteoarthritis and joint injuries.
The method uses a benchtop micromagnetic resonance relaxometry (µMRR) device to measure subtle changes in iron concentration in spent culture media. Crucially, the test is non-destructive and delivers results in under an hour, compared with traditional assays that take up to three weeks and render cells unusable.
As first author Yanmeng Yang put it in a press release: “One of the key challenges in cartilage regeneration is the inability to reliably predict whether MSCs will retain their chondrogenic potential during manufacturing.” She adds that the new approach “enables early identification of suboptimal cell batches during culture, enhancing quality control efficiency, reducing manufacturing costs, and accelerating clinical translation.”
The researchers also found that supplementing cultures with ascorbic acid helps regulate iron flux, significantly improving cartilage-forming outcomes. By enabling real-time quality control during manufacturing, the method could make MSC-based therapies more consistent and clinically viable.
“By monitoring iron flux in real-time without destroying the cells, we can gain actionable insights into a cell batch’s chondrogenic potential,” said corresponding author Jongyoon Han. He adds that the findings “pav[e] the way for more consistent and clinically viable regenerative medicine for cartilage regeneration.”
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
